Nancy Lee, MD
- Detectable Plasma EBV DNA Cohort (randomized phase II): The primary objective is to determine whether substituting adjuvant CDDP and 5-FU with gemcitabine and paclitaxel will result in superior progression-free survival.
- Undetectable Plasma EBV DNA Cohort (phase III): The primary objective is to determine whether omitting adjuvant CDDP and 5-FU (observation alone in the adjuvant setting) will result in noninferior overall survival as compared with those patients receiving adjuvant CDDP and 5-FU chemotherapy.
Biopsy proven (from primary lesion and/or lymph nodes) diagnosis of stage II-IVB non-metastatic cancer of the nasopharynx; detectable pre-treatment plasma EBV DNA.
- Randomized phase II: 126
- Phase III: 632
Available via the National Cancer Institute (NCI) Cancer Trials Support Unit (CTSU) website